Key Points
- Director purchase: Senseonics Director Edelman Steven bought 10,000 shares at an average price of $6.55 on Nov 10 for $65,500, bringing his direct stake to 74,708 shares (a 15.45% increase), according to an SEC Form 4 filing.
- Analyst sentiment: The stock carries an average analyst rating of "Buy" with an average target of $22.70, and individual recent price-target moves range from Barclays' $31 target to TD Cowen's $15 target.
- Market snapshot: Shares traded around $6.18 with a 52-week range of $5.00–$28.00, a market cap of about $252.7M, and a negative trailing P/E, reflecting unprofitable operations.
Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report) Director Edelman Steven bought 10,000 shares of the firm's stock in a transaction on Monday, November 10th. The shares were bought at an average cost of $6.55 per share, with a total value of $65,500.00. Following the transaction, the director directly owned 74,708 shares of the company's stock, valued at approximately $489,337.40. This trade represents a 15.45% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Senseonics Stock Up 0.1%
Shares of NYSE:SENS traded up $0.00 during trading on Friday, hitting $6.18. 313,275 shares of the company's stock traded hands, compared to its average volume of 424,164. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. Senseonics Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $28.00. The company has a 50-day moving average price of $8.22 and a 200-day moving average price of $9.74. The company has a market cap of $252.67 million, a price-to-earnings ratio of -47.58 and a beta of 0.79.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the company. Barclays reaffirmed an "overweight" rating and set a $31.00 target price (up from $1.50) on shares of Senseonics in a research report on Wednesday, November 5th. TD Cowen lowered their price objective on Senseonics from $25.00 to $15.00 and set a "buy" rating on the stock in a research report on Wednesday, November 5th. Stifel Nicolaus started coverage on shares of Senseonics in a research note on Tuesday, October 21st. They set a "hold" rating and a $9.00 target price for the company. HC Wainwright lifted their price objective on shares of Senseonics to $18.50 and gave the stock a "buy" rating in a research report on Thursday, November 6th. Finally, Lake Street Capital upgraded shares of Senseonics to a "strong-buy" rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $22.70.
Check Out Our Latest Stock Report on SENS
Hedge Funds Weigh In On Senseonics
A number of large investors have recently modified their holdings of SENS. First Light Asset Management LLC raised its position in Senseonics by 666.7% during the second quarter. First Light Asset Management LLC now owns 35,708,124 shares of the company's stock valued at $17,011,000 after acquiring an additional 31,050,619 shares in the last quarter. Hood River Capital Management LLC bought a new stake in Senseonics during the second quarter worth about $3,775,000. Sio Capital Management LLC bought a new stake in Senseonics during the 2nd quarter worth about $2,312,000. UBS Group AG lifted its position in Senseonics by 409.0% during the 3rd quarter. UBS Group AG now owns 4,248,519 shares of the company's stock valued at $1,852,000 after purchasing an additional 3,413,866 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Senseonics by 26.6% during the 2nd quarter. Geode Capital Management LLC now owns 8,701,129 shares of the company's stock worth $4,147,000 after acquiring an additional 1,828,302 shares during the period. 12.36% of the stock is owned by hedge funds and other institutional investors.
About Senseonics
(
Get Free Report)
Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
